Press release
Idiopathic Pulmonary Fibrosis (IPF) Clinical Market to Reach USD 6.2 Billion by 2030
Idiopathic Pulmonary Fibrosis (IPF) Clinical
The market includes diagnostic tools, anti-fibrotic drugs, supportive care therapies, pulmonary rehabilitation, oxygen therapy, and clinical management programs essential for improving patient quality of life and slowing disease progression.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73630
Key Takeaways
• Market Size 2023: USD 3.8 billion
• Market Size 2030: USD 6.2 billion
• CAGR (2024-2030): 7.4%
• Largest Segment: Anti-fibrotic drugs (pirfenidone, nintedanib)
• Fastest-Growing Segment: Diagnostic tools including HRCT and biomarker-based tests
Market Story
Idiopathic Pulmonary Fibrosis (IPF) is a life-limiting interstitial lung disease affecting adults over 50. Demand for early diagnosis, advanced imaging, and effective clinical management is increasing globally. Although IPF has no cure, early intervention with anti-fibrotic therapies can slow disease progression significantly.
Key components of the IPF clinical market include:
• High-resolution CT (HRCT) imaging
• Pulmonary function tests (PFTs)
• Genetic/biomarker diagnostics
• Anti-fibrotic drugs (pirfenidone & nintedanib)
• Corticosteroids & symptom management therapies
• Pulmonary rehabilitation programs
• Oxygen therapy systems
• Digital monitoring & telehealth solutions
Growth is primarily fueled by increasing disease awareness, improved diagnostic access, clinical trial advancements, and rising healthcare investment in chronic respiratory diseases.
Market Segments
By Treatment Type
• Anti-Fibrotic Drugs (Largest Segment)
- Pirfenidone
- Nintedanib
• Corticosteroids & Immunosuppressants
• Symptomatic Management Drugs
• Combination Therapies
• Pipeline Drugs (Emerging)
- Anti-inflammatory agents
- Gene therapy candidates
- Anti-fibrotic monoclonal antibodies
Anti-fibrotic therapies dominate due to proven ability to slow lung scarring.
By Diagnostic Method
• High-Resolution CT (HRCT) Scans (Gold Standard)
• Pulmonary Function Tests (PFTs)
• Biomarker Tests (Growing Adoption)
• Bronchoscopy & Lung Biopsy
• Genetic Testing (Emerging)
HRCT remains the most widely used diagnostic imaging technology.
By Clinical Service
• Hospital-Based IPF Care (Largest Share)
• Pulmonology Clinics
• Telehealth & Remote Monitoring
• Pulmonary Rehabilitation Centers
• Specialized IPF Treatment Programs
Pulmonary rehab is growing due to proven benefits in symptom relief and quality of life.
By End User
• Hospitals & Specialty Lung Centers (Largest End User)
• Diagnostic Imaging Centers
• Research Institutes & Clinical Trial Sites
• Home Healthcare Providers
• Pharmaceutical Companies
Hospitals dominate due to routine monitoring and treatment needs for chronic IPF patients.
Explore Full Report here: https://exactitudeconsultancy.com/reports/73630/idiopathic-pulmonary-fibrosis-clinical-market
Recent Industry Developments
• 2024 - Boehringer Ingelheim advanced its pipeline of combination therapies targeting lung fibrosis.
• 2023 - Roche expanded clinical research for novel anti-fibrotic agents improving lung function decline rate.
• 2023 - GSK initiated trials for next-generation IPF-targeting biologics.
• 2023 - Veracyte launched advanced genomic tests to support accurate ILD diagnosis.
• 2023 - ResMed expanded digital respiratory monitoring tools for chronic lung patients.
Expert Quote
"With rising global prevalence of lung fibrosis and limited therapeutic options, the IPF clinical market is moving toward early diagnosis and advanced anti-fibrotic treatments-fundamental for improving patient outcomes."
- Irfan Tamboli, Business Development Executive, Exactitude Consultancy
Key Market Drivers
1. Rising Prevalence of IPF
Increasing incidence in aging populations boosts demand for diagnostics and clinical care.
2. Growing Adoption of Anti-Fibrotic Therapies
Pirfenidone and nintedanib remain the cornerstone of IPF treatment.
3. Advancements in Diagnostic Imaging
HRCT and biomarker-based tools support earlier and more accurate diagnosis.
4. Increased Clinical Trials & Innovation
Pharmaceutical companies actively pursue novel drugs and gene therapy approaches.
5. Expansion of Telehealth & Home Monitoring
COVID-19 accelerated adoption of remote lung monitoring and virtual consultations.
Forecast Outlook (2024-2030)
Future developments will include:
• AI-based imaging tools for early detection
• Integration of home spirometry & wearable lung monitors
• Breakthrough biologics targeting fibrosis pathways
• Personalized medicine approaches using biomarkers
• Advanced drug combinations improving survival rates
By 2030, IPF management will rely heavily on precision diagnostics, next-generation anti-fibrotics, and digital remote care ecosystems.
Regional Insights
North America
Largest market due to higher diagnostic access, established IPF care centers, and strong pharmaceutical pipelines.
Europe
Highly structured ILD management programs and strong clinical research networks support growth.
Asia-Pacific (Fastest Growing Region)
Rising awareness, increasing aging population, and improved healthcare access in China, Japan, and South Korea.
Latin America & Middle East
Gradual rise in diagnosis rates supported by expanding imaging infrastructure.
Conclusion
The Idiopathic Pulmonary Fibrosis Clinical Market is expanding steadily as healthcare systems enhance diagnostic accuracy, improve clinical management, and accelerate development of new anti-fibrotic therapies. With rising global prevalence and increased investment in chronic respiratory disease research, the market will continue to evolve significantly through 2030.
This report is also available in the following languages : Japanese (特発性肺線維症の臨床市場), Korean (특발성 폐섬유증 임상 시장), Chinese (特发性肺纤维化临床市场), French (Marché clinique de la fibrose pulmonaire idiopathique), German (Klinischer Markt für idiopathische Lungenfibrose), and Italian (Mercato clinico della fibrosi polmonare idiopatica), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/73630
Related Reports
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) Clinical Market
https://exactitudeconsultancy.com/reports/73655/human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-clinical-market
High-Grade Glioma Clinical Market
https://exactitudeconsultancy.com/reports/73656/high-grade-glioma-clinical-market
Lennox-Gastaut Syndrome Clinical Market
https://exactitudeconsultancy.com/reports/73657/lennox-gastaut-syndrome-clinical-market
Frozen Shoulder Syndrome Clinical Market
https://exactitudeconsultancy.com/reports/73658/frozen-shoulder-syndrome-clinical-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Idiopathic Pulmonary Fibrosis (IPF) Clinical Market to Reach USD 6.2 Billion by 2030 here
News-ID: 4293196 • Views: …
More Releases from Exactitude Consultancy
Gaucher Disease Clinical Market to Reach USD 2.9 Billion by 2030
The Global Gaucher Disease Clinical Market is expanding steadily as advancements in enzyme replacement therapy (ERT), substrate reduction therapy (SRT), and gene therapy significantly improve outcomes for patients with this inherited lysosomal storage disorder. According to Exactitude Consultancy, the market is expected to grow from USD 1.8 billion in 2023 to USD 2.9 billion by 2030, achieving a CAGR of 6.5%.
The market encompasses diagnostics, drug therapies, patient monitoring, newborn screening…
Dengue Fever Clinical Market to Reach USD 6.4 Billion by 2030
The Global Dengue Fever Clinical Market is accelerating as healthcare systems worldwide face rising dengue infection rates driven by climate change, rapid urbanization, and expanding mosquito habitats. According to Exactitude Consultancy, the market is projected to grow from USD 3.2 billion in 2023 to USD 6.4 billion by 2030, at a strong CAGR of 9.8%.
The market includes diagnostics, treatment, vaccines, supportive care, surveillance systems, and clinical management services-playing a crucial…
Protein Expression Market to Reach USD 8.7 Billion by 2030
The Global Protein Expression Market is experiencing significant growth as biotechnology, pharmaceuticals, contract manufacturing, and academic research intensify their focus on recombinant protein production. According to Exactitude Consultancy, the market is expected to rise from USD 4.1 billion in 2023 to USD 8.7 billion by 2030, expanding at a healthy CAGR of 10.9%.
Protein expression technologies enable the production of therapeutic proteins, enzymes, antibodies, vaccines, and research-grade proteins-making them essential tools…
Ready-to-Use Pharmaceutical Packaging Market to Reach USD 14.1 Billion by 2030
The Global Ready-to-Use (RTU) Pharmaceutical Packaging Market is expanding rapidly as biopharmaceutical companies, CDMOs, vaccine manufacturers, and injectables producers shift toward sterile, prevalidated, and fill-finish-ready packaging formats. According to Exactitude Consultancy, the market is expected to grow from USD 6.1 billion in 2023 to USD 14.1 billion by 2030, registering an impressive CAGR of 11.7%.
RTU packaging-prewashed, depyrogenated, sterilized, and ready for aseptic filling-reduces contamination risks, improves output efficiency, eliminates complex…
More Releases for IPF
Cough in Idiopathic Pulmonary Fibrosis (IPF) Market Massive Growth opportunity A …
Introduction
Idiopathic pulmonary fibrosis (IPF) is a rare, progressive lung disease characterized by scarring of the lung tissue, leading to declining lung function and breathing difficulties. Among its debilitating symptoms, chronic cough is one of the most distressing, affecting over 80% of IPF patients. Persistent cough significantly worsens patients' quality of life, disrupts sleep, and increases anxiety, yet therapeutic options remain limited.
The Cough in IPF Market is at a transformative stage,…
Idiopathic Pulmonary Fibrosis (IPF) Market Size, Share, Industry, Forecast and o …
Idiopathic Pulmonary Fibrosis (IPF) Market
Global Idiopathic Pulmonary Fibrosis (IPF) Market Set for Remarkable Growth, Projected to Reach US$ 4,614.3 Million by 2030
The global Idiopathic Pulmonary Fibrosis (IPF) market, valued at US$ 2,184.4 million in 2022, is poised for substantial expansion, with projections reaching up to US$ 4,614.3 million by 2030. Anticipated to exhibit a Compound Annual Growth Rate (CAGR) of 10.1% during the forecast period from 2024 to 2031, the…
Breath of Hope: IPF Drug Pipeline Landscape (2022)
Market Outlook:
Breath of Hope: IPF Drug Pipeline Landscape (2022)
The IPF Drug Pipeline Landscape embarks on a transformative journey, offering a breath of hope for individuals grappling with Idiopathic Pulmonary Fibrosis (IPF). This comprehensive outlook explores the unfolding strategies, innovations, and breakthroughs that promise to reshape the trajectory of IPF treatment over the next decade.
Market Drivers:
Precision Therapies on the Horizon: At the forefront of the IPF Drug Pipeline, the prospect of…
Idiopathic Pulmonary Fibrosis (IPF) Market to Reach US$ 6,825.3 Million by 2033 …
The newly published report by IMARC Group, titled "Idiopathic Pulmonary Fibrosis (IPF) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033″, presents a comprehensive analysis of the idiopathic pulmonary fibrosis (IPF) market. The report provides an overview of the market trends, growth prospects, investment opportunities, and industry prospects, as well as an analysis of the disease overview, market scenario, and growth trends. In addition, the report offers competitor…
Recent Release: Global Idiopathic pulmonary fibrosis (IPF) Market To 2023
MarketResearchReports.Biz presents this most up-to-date research on "Idiopathic pulmonary fibrosis (IPF)- Epidemiology Forecast To 2023"
Idiopathic pulmonary fibrosis (IPF) - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Idiopathic pulmonary fibrosis (IPF) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Idiopathic pulmonary fibrosis (IPF) prevalent or incident cases segmented by age, sex and…
Idiopathic Pulmonary Fibrosis (IPF) Pipeline, A Novel Advancement for the Treatm …
The study analyzed that the IPF pipeline comprised of 97 therapeutic candidates, of which 15 are in Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. Various drugs are being developed as novel and promising therapeutics for the treatment of IPF.
Browse the Report Summary at: www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market
Insights on pipeline segments
As per the findings of research, it was found…
